Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Aldehyde doai
Reexamination Certificate
2007-01-02
2007-01-02
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Aldehyde doai
C514S729000
Reexamination Certificate
active
10016726
ABSTRACT:
Preferred compositions used to inhibit the growth of bacteria, fungi and yeast include perillyl aldehyde as an active ingredient. Other active ingredients include perillyl alcohol. The compositions are formed as gels, creams, liquids and dry formulations.
REFERENCES:
patent: 5110832 (1992-05-01), Chastain et al.
patent: 5294645 (1994-03-01), Chastain et al.
patent: 5308873 (1994-05-01), Chastain et al.
patent: 5411992 (1995-05-01), Eini et al.
patent: 5487988 (1996-01-01), Chang et al.
patent: 5763415 (1998-06-01), Sukumar
patent: 5795566 (1998-08-01), Joulain et al.
Kurita et al., “Antifungal activity and molecular orbital energies of aldehyde compounds from oils of higher plants”, Agricultural and Biological Chemistry (1979), 43(11), pp. 2365-2371 (see enclosed copy of abstract).
Pamela L. Crowell, Rebekah R. Chang, Zhibin Ren, Charles E. Elson, and Michael N. Gould; Selective Inhibition of Isoprenylation of 21-26-kDa Proteins by the Anticarcinogen d-Limonene and its Metabolites;The Journal of Biological Chemistry; 1991; vol. 266, No. 26, pp. 17679, 17681-17685; USA.
Jill D. Haag, Mary J. Lindstrom, and Michael N. Gould; Limonene-induced Regression of Mammary Carcinomas;Cancer Research; 1992; pp. 4021-4026; USA.
Bandaru S. Reddy, C-X Wang, Hanan Samaha, Ronald Lubet, Vernone E. Steele, Gary J. Kelloff, and Chinthalapally V. Rae; Chemoprevention of Colon Carcinogenesis by Dietary Perillyl Alcohol;Cancer Research; 1997; pp. 420-425; USA.
Gregory H. Ripple, Michael N. Gould, James A. Stewart, Kendra D. Tutsch, Rhoda Z. Arzoomanian, Dona Alberti, Chris Feierabend, Marcia Pomplun, George Wilding, and Howard H. Bailey; Phase I Clinical Trial of Perillyl Alcohol Administered Daily;Clinical Cancer Research; 1998; pp. 1159-1164; USA.
Margaret Barthelman, Weixing Chen, Helen L. Gensler, Chuanshu Huang, Zigang Dong, and G. Tim Bowden; Inhibitory Effects of Perillyl ALcohol on UVB-induced Murine Skin Cancer and AP-1 Transactivation;Cancer Research; 1998; pp. 711-716; USA.
Piet J. M. Boon, Dennis van der Boon, and Gerard J. Mulder; Cytotoxicity and Biotransformation of the Anticancer Drug Perillyl Alcohol in PC12 Cellsa and in the Rat; Toxicology and Applied Pharmacology; 2000;pp. 55-61; USA.
Gregory H. Ripple, Michael N. Gould, Rhonda Z. Arzoomanian, Dona Alberti, Chris Feierabend, Kim Binger, Kendra D. Tutsch, Marcia Pomplun, Any Wahamaki, Rebecca, Marnocha, George Wilding, and Howard H. Bailey; Phase I Clinical and Pharmacokinetic Study of Perillyl Alcohol Administered Four TImes a Day,Clinical Cancer Research; 2000; pp. 390-396; USA.
Gary R. Hudes, Christine E. Szarka, Andrea Adams, Sulabha Ranganathan, Robert A. McCauley, Louis M. Weiner, Corey J. Langer, Samuel Litwin, Gwen Yeslow, Theresa Halberr, Mingxin Qian, and James M. Gallo; Phase I Pharmacokinetic Trial of Perillyl Alcohol (NSC 641066 in Patients with Refractory Solid Malignancies;Clinical Cancer Research; 2000; pp. 3071-3080; USA.
Nobuyuki Kurita, Makoto Miyaji, Ryuichiro Kurane, and Yoshimasa Takahara; Antifungal Activity of Componets of Essential Oils;Agric. Biol. Chem; 1981; vol. 45, pp. 945-952; USA.
Montes-Morales Naida
Zayas-Rivera José
Hoglund Heath W.
Hoglund & Pamias PSC
Weddington Kevin E.
Zaycor Industries Corp.
LandOfFree
Medical application of oxidized monoterpenes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medical application of oxidized monoterpenes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical application of oxidized monoterpenes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3783512